Cargando…

Pre-induction LDH as a prognostic factor for outcome of high dose chemotherapy (HDCT) for germ cell tumours relapsing or refractory to conventional chemotherapy

Detalles Bibliográficos
Autores principales:	Shamash, J, Oliver, R T D, Gallagher, C J, Newland, A C, Lister, T A, Kelsey, S, Gupta, R K, O'Doherty, C A
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2000
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363262/ https://www.ncbi.nlm.nih.gov/pubmed/10864212 http://dx.doi.org/10.1054/bjoc.1999.1140

Ejemplares similares

Prediction of relapse after lymph node dissection for germ cell tumours: can salvage chemotherapy be avoided?
por: Berney, D M, et al.
Publicado: (2001)

Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumours
por: McNeish, I A, et al.
Publicado: (2004)

Conventional-Dose versus High-Dose Chemotherapy for Relapsed Germ Cell Tumors
por: McHugh, Deaglan J., et al.
Publicado: (2018)

P110: Outcome of high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) as first salvage treatment for relapsed or refractory classical Hodgkin Lymphoma (cHL) in the era of PET-adapted strategy among Italian centers
por: Viviani, Simonetta, et al.
Publicado: (2022)

Survival outcomes of patients with germ cell tumors treated with high-dose chemotherapy for refractory or relapsing disease
por: Zschäbitz, Stefanie, et al.
Publicado: (2018)

Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group
por: Powles, T, et al.
Publicado: (2003)

IPM chemotherapy in cytokine refractory renal cell cancer
por: Shamash, J, et al.
Publicado: (2003)

Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse
por: Hain, S F, et al.
Publicado: (2000)

GAMEC – a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours
por: Shamash, J, et al.
Publicado: (2007)

GAMEC – a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours
por: Shamash, J, et al.
Publicado: (2007)

MEDB-35. Relationship between genetic profile, histology, clinical features and long-term outcome in young children medulloblastoma (YCMB) treated with upfront high dose chemotherapy (HDCT) in Italy
por: Garrè, Maria Luisa, et al.
Publicado: (2022)

Salvage chemotherapy for adults with relapsed or refractory lymphoma in Malawi
por: Kaimila, Bongani, et al.
Publicado: (2017)

Hematopoietic stem cell mobilization strategies to support high-dose chemotherapy: A focus on relapsed/refractory germ cell tumors
por: Porfyriou, Eleni, et al.
Publicado: (2021)

Germ cell tumour chemotherapy.
por: Horwich, A.
Publicado: (1989)

Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience
por: Olgun, Nur, et al.
Publicado: (2022)

In vitro testing of calcium channel blockers and cytotoxic chemotherapy in B-cell low-grade non-Hodgkin's lymphoma.
por: Shamash, J., et al.
Publicado: (1998)

Novel Therapies and Approaches to Relapsed/Refractory HL Beyond Chemotherapy
por: Mina, Alain Antoine, et al.
Publicado: (2019)

Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma
por: Wieczorek, Aleksandra, et al.
Publicado: (2023)

A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice
por: Newton, C., et al.
Publicado: (2019)

Managing relapsed refractory lymphoma with palliative oral chemotherapy: A multicentre retrospective study
por: Bulley, Simon J., et al.
Publicado: (2022)

ML-02 Chemotherapy for patients with relapsed or refractory primary CNS lymphoma
por: Nagane, Motoo, et al.
Publicado: (2020)

Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia
por: Popescu, Bogdan, et al.
Publicado: (2019)

Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma
por: Imaya, Masayuki, et al.
Publicado: (2022)

Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET
por: Bokemeyer, C, et al.
Publicado: (2002)

Germ cell cancer in pregnancy – Successfully treated with chemotherapy and surgery
por: Reid, I., et al.
Publicado: (2023)

Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re‐induction chemotherapy
por: Ruan, Min, et al.
Publicado: (2021)

Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results
por: Goldsmith, Kelly C., et al.
Publicado: (2023)

Mogamulizumab versus investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma
por: Phillips, Adrienne A., et al.
Publicado: (2019)

The Use of Salvage Chemotherapy for Patients with Relapsed Testicular Germ Cell Tumor (GCT) in Canada: A National Survey
por: Al-Ezzi, Esmail M., et al.
Publicado: (2023)

Allogeneic or autologous stem cell transplantation following salvage chemotherapy for adults with refractory or relapsed acute lymphoblastic leukemia
por: Martino, R, et al.
Publicado: (1998)

Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib-based chemotherapy
por: Zhao, Junmei, et al.
Publicado: (2015)

Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy
por: Klement, Piroska, et al.
Publicado: (2022)

Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia
por: Cummins, K D, et al.
Publicado: (2014)

Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia
por: Cummins, K D, et al.
Publicado: (2014)

Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
por: Yuan, Xianggui, et al.
Publicado: (2022)

P1079: COMPARISON OF NOVEL SALVAGE REGIMENS AND TRADITIONAL SALVAGE CHEMOTHERAPY IN RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA
por: Ermann, D., et al.
Publicado: (2022)

A Randomised Phase 2 Trial of Intensive Induction Chemotherapy (CBOP/BEP) and Standard BEP in Poor-prognosis Germ Cell Tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604)
por: Huddart, Robert A., et al.
Publicado: (2015)

Overcoming Chemotherapy Resistance in Germ Cell Tumors
por: Országhová, Zuzana, et al.
Publicado: (2022)

Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604)
por: Cafferty, Fay H., et al.
Publicado: (2020)

A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer
por: Shamash, J, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_cf6f3gask9u31c5fsobbbbbgum